Dan Leonard
Stock Analyst at UBS
(4.08)
# 523
Out of 5,090 analysts
308
Total ratings
57.47%
Success rate
9.95%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $170 → $180 | $145.49 | +23.72% | 23 | Nov 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $14 | $17.77 | -21.22% | 7 | Nov 7, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $65 → $70 | $61.68 | +13.49% | 12 | Nov 6, 2025 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $48.03 | -10.47% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $102.02 | +7.82% | 11 | Oct 30, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $225 → $250 | $225.85 | +10.69% | 17 | Oct 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $572.77 | +3.01% | 18 | Oct 23, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $101.06 | -47.56% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $9.22 | +62.69% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $548.12 | -44.36% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $226.25 | -0.55% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,414.86 | -4.58% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $317.69 | -2.42% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $317.05 | -2.22% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $100.79 | +14.10% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $91.74 | +7.91% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $10.93 | +128.73% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $184.31 | +0.37% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $9.54 | -5.66% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $27.79 | +25.94% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $128.96 | +55.09% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.70 | +197.30% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $244.55 | -71.38% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $14.75 | -52.54% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $394.81 | -12.62% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $185.80 | +39.94% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $182.51 | -20.55% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $74.97 | +20.05% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $47.01 | +35.40% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $258.39 | +31.58% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $22.11 | +8.55% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $7.09 | +393.65% | 12 | Aug 14, 2019 |
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $170 → $180
Current: $145.49
Upside: +23.72%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $14
Current: $17.77
Upside: -21.22%
Bio-Techne
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $61.68
Upside: +13.49%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $48.03
Upside: -10.47%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $102.02
Upside: +7.82%
IQVIA Holdings
Oct 29, 2025
Maintains: Buy
Price Target: $225 → $250
Current: $225.85
Upside: +10.69%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $572.77
Upside: +3.01%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $101.06
Upside: -47.56%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $9.22
Upside: +62.69%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $548.12
Upside: -44.36%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $226.25
Upside: -0.55%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,414.86
Upside: -4.58%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $317.69
Upside: -2.42%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $317.05
Upside: -2.22%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $100.79
Upside: +14.10%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $91.74
Upside: +7.91%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $10.93
Upside: +128.73%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $184.31
Upside: +0.37%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $9.54
Upside: -5.66%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $27.79
Upside: +25.94%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $128.96
Upside: +55.09%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.70
Upside: +197.30%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $244.55
Upside: -71.38%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $14.75
Upside: -52.54%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $394.81
Upside: -12.62%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $185.80
Upside: +39.94%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $182.51
Upside: -20.55%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $74.97
Upside: +20.05%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $47.01
Upside: +35.40%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $258.39
Upside: +31.58%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $22.11
Upside: +8.55%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $7.09
Upside: +393.65%